Cargando…

A phase II, open-label, non-randomized, prospective study assessing paclitaxel, carboplatin and metformin in the treatment of advanced stage ovarian carcinoma

OBJECTIVE: The purpose of this study was to assess the efficacy and tolerability of a paclitaxel, carboplatin and metformin regimen in the first-line treatment of advanced-stage ovarian, fallopian tube, and primary peritoneal carcinoma. METHODS: Eligible subjects underwent surgery and 6 cycles of ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Micha, John P., Rettenmaier, Mark A., Bohart, Randy D., Goldstein, Bram H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995875/ https://www.ncbi.nlm.nih.gov/pubmed/36509462 http://dx.doi.org/10.3802/jgo.2023.34.e15

Ejemplares similares

Robotic-Assisted Surgery for the Treatment of Breast and Cervical Cancers
por: Micha, John P., et al.
Publicado: (2022)

Hormone Therapy and Risk of Breast Cancer: Where Are We Now?
por: Micha, John P., et al.
Publicado: (2022)

Phase I study of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer
por: Broekman, K. Esther, et al.
Publicado: (2020)

Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial
por: Li, Li, et al.
Publicado: (2018)

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
por: Mullany, Sally, et al.
Publicado: (2020)

Comparison of paclitaxel liposomes combined with carboplatin versus paclitaxel combined with carboplatin in the treatment of advanced ovarian cancer
por: Tan, Xiangbin, et al.
Publicado: (2023)

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer
por: Camidge, D. Ross, et al.
Publicado: (2014)

A phase II study of sequential carboplatin, paclitaxel and topotecan in patients with previously untreated advanced ovarian cancer
por: Guppy, A E, et al.
Publicado: (2004)

Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial.
por: Zielinski, C. C., et al.
Publicado: (1998)

Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group
por: du Bois, A, et al.
Publicado: (2012)

Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial
por: Zhou, T., et al.
Publicado: (2021)

A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer
por: Harries, M, et al.
Publicado: (2004)

Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
por: Tao, Yin, et al.
Publicado: (2022)

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale
por: Isakoff, Steven J, et al.
Publicado: (2017)

Does the addition of metformin to carboplatin treatment decreases ovarian reserve damage associated with carboplatin usage?
por: Ayhan, Sevgi, et al.
Publicado: (2023)

Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin
por: Dessai, S. B., et al.
Publicado: (2016)

Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non‐Small Cell Lung Cancer
por: Takayama, Koichi, et al.
Publicado: (2019)

Dramatic clinical response following dabrafenib and trametinib therapy in a heavily pretreated low grade serous ovarian carcinoma patient with a BRAF V600E mutation
por: Mendivil, Alberto A., et al.
Publicado: (2018)

Cranial and intra-axial metastasis originating from a primary ovarian Dysgerminoma()
por: Beck, Tiffany L., et al.
Publicado: (2019)

A phase II trial of concurrent chemoradiotherapy with weekly paclitaxel and carboplatin in advanced oesophageal carcinoma
por: Xia, Yi, et al.
Publicado: (2018)

Phase 1 study of veliparib with carboplatin and weekly paclitaxel in Japanese patients with newly diagnosed ovarian cancer
por: Nishio, Shin, et al.
Publicado: (2017)

Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
por: Jamal, Rahima, et al.
Publicado: (2017)

A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy‐Naïve Advanced or Metastatic Nonsquamous Non‐Small Cell Lung Cancer
por: Marrone, Kristen A., et al.
Publicado: (2018)

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study
por: van Meerten, E, et al.
Publicado: (2006)

Phase I/II study of DHA–paclitaxel in combination with carboplatin in patients with advanced malignant solid tumours
por: Harries, M, et al.
Publicado: (2004)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Carboplatin plus nab‐paclitaxel for recurrent small cell lung cancer: A phase II study
por: Ikeda, Naoya, et al.
Publicado: (2022)

A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer.
por: Siddiqui, N., et al.
Publicado: (1997)

The impact of paclitaxel and carboplatin chemotherapy on the autonomous nervous system of patients with ovarian cancer
por: Dermitzakis, Emmanouil V., et al.
Publicado: (2016)

Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute
por: Hainsworth, John D, et al.
Publicado: (2015)

A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
por: Bafaloukos, Dimitrios, et al.
Publicado: (2010)

Low-grade pelvic masses with spindle cell and fibroblastic proliferation: a case report
por: Micha, John, et al.
Publicado: (2007)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial
por: Hori, Kensuke, et al.
Publicado: (2021)

Phase II Clinical Trial of Genexol® (Paclitaxel) and Carboplatin for Patients with Advanced Non-small Cell Lung Cancer
por: Kim, Han Jo, et al.
Publicado: (2011)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer
por: Yuan, Yuan, et al.
Publicado: (2023)

Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
por: Rosenthal, Mark, et al.
Publicado: (2020)

Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
por: Huang, Liang, et al.
Publicado: (2015)

Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan
por: Harano, Kenichi, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_orf3bkjhilge26j9st91fr76l8